Similarly, subjects with CRP levels >ULN were more likely to have relapsed breast cancer (OR 2.66, 95% CI 1.34–5.28, p = 0.005), while subjects with IL-6 levels >ULN had no increased likelihood of relapsed breast cancer (OR 0.62, 95% CI 0.20–1.90, p = 0.402). The gene discussed is IL6; the disease is breast carcinoma.